[Elacestrant - ER+/HER2-, locally advanced, or metastatic breast cancer with an activating ESR1 mutation]

Bull Cancer. 2024 Jul-Aug;111(7-8):628-629. doi: 10.1016/j.bulcan.2024.03.005. Epub 2024 May 13.
[Article in French]
No abstract available

Keywords: Aromatase inhibitor; Cancer du sein; ESR1 mutation; Elacestrant; Endocrine therapy; Hormonothérapie; Inhibiteur aromatase; Inhibiteur sélectif du récepteur des œstrogènes; Metastatic breast; Mutation ESR1; Selective estrogen receptor degrader (SERD).

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / pathology
  • Estrogen Receptor alpha* / genetics
  • Estrogen Receptor alpha* / metabolism
  • Female
  • Fulvestrant / therapeutic use
  • Humans
  • Mutation
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / metabolism

Substances

  • Estrogen Receptor alpha
  • ESR1 protein, human
  • Receptor, ErbB-2
  • Fulvestrant
  • Antineoplastic Agents, Hormonal
  • Receptors, Estrogen